ClinicalTrials.gg

Program

selinexor

Also written as “Selinexor”, “Selinexor (combination therapy)” and “Selinexor 40 mg”.

Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Primary Myelofibrosis · Endometrial Neoplasms · Glioblastoma, led by 6 companies.

Furthest: phase 3, since Oct 13, 201540 company-led studies, 12 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Karyopharm Therapeutics317 open or runningphase 3since Oct 13, 2015May 16, 2012Dec 2026phase 3 · NCT04442022
Antengene40 open or runningphase 2since Apr 30, 2019Apr 30, 2019none ahead
Oncotherapeutics22 open or runningphase 1since Aug 12, 2020Aug 12, 2020Apr 1, 2027phase 1 · NCT06225310
AbbVie11 open or runningphase 3since Nov 28, 2023Nov 28, 2023Dec 2027phase 3 · NCT06158841
Qilu Pharmaceutical11 open or runningphase 3since Aug 13, 2025Aug 13, 2025Dec 2027phase 3 · NCT07138209
Sarah Cannon Research Institute11 open or runningphase 2since Mar 1, 2021Mar 1, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 26 studies since May 16, 2012.

  1. Jun 10, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT04442022 · 501 enrolled · United States, China, Israel and more
  2. Aug 12, 2020Oncotherapeutics's first study: phase 1 study in Multiple MyelomaNew to OncotherapeuticsOncotherapeutics · NCT04519476 · 22 planned · United States
  3. Sep 9, 2020Phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT04562870 · 112 enrolled · United States, China, France and more
  4. Sep 14, 2020Phase 3 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT04562389 · 353 enrolled · United States, Australia, Belgium and more
  5. Feb 22, 2021Phase 2 study in MelanomaKaryopharm Therapeutics · NCT04768881 · 15 enrolled · United States
  6. Mar 1, 2021Sarah Cannon Research Institute's first study: phase 2 study in Multiple MyelomaNew to Sarah Cannon Research InstituteSarah Cannon Research Institute · NCT04782687 · 73 enrolled · United States
  7. Apr 17, 2021Phase 2 study in Colorectal NeoplasmsKaryopharm Therapeutics · NCT04854434 · 13 enrolled · United States
  8. Feb 9, 2022Phase 2 study in Lymphoma, Large B-Cell, DiffuseAntengene · NCT05265975 · 54 enrolled · China
  9. Apr 26, 2022Phase 1 study in Lymphoma, Large B-Cell, DiffuseAntengene · NCT05354362 · 7 enrolled · China
  10. Nov 3, 2022Phase 3 study in Endometrial NeoplasmsKaryopharm Therapeutics · NCT05611931 · 257 enrolled · United States, Australia, Belgium and more
  11. Jul 24, 2023Phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT05980806 · 58 planned · United States, Belgium, Bulgaria and more
  12. Nov 7, 2023Phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310 · 30 planned · United States
  13. Nov 28, 2023AbbVie's first study: phase 3 study in Multiple MyelomaNew to AbbVieAbbVie · NCT06158841 · 421 enrolled · United States, Australia, Austria and more
  14. Aug 13, 2025Qilu Pharmaceutical's first study: phase 3 study in RecurrenceNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07138209 · 228 planned · China

Ahead

  1. Dec 2026Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT04442022
  2. Dec 2026Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseKaryopharm Therapeutics · NCT02227251
  3. Apr 1, 2027Primary completion: phase 1 study in Multiple MyelomaOncotherapeutics · NCT06225310
  4. Jun 2027Primary completion: phase 2 study in Primary MyelofibrosisKaryopharm Therapeutics · NCT05980806

TargetBeta

XPO1 →read by rule
“An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), ”NCIt, by rule
“Exportin-1 inhibitor”ChEMBL 37, by rule

Other programs on XPO1

ProgramCompanyFurthest phaseStudies
TQB3107Sino Biopharmaceuticalphase 11

Studies

All 40 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07138209Recurrence · China3RecruitingQilu PharmaceuticalDec 2027228
NCT06158841Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingAbbVieDec 2027421
NCT06225310Multiple Myeloma · United States1RecruitingOncotherapeuticsApr 1, 202730
NCT05980806Primary Myelofibrosis · United States, Belgium, Bulgaria and more2RecruitingKaryopharm TherapeuticsJun 202758
NCT05611931Endometrial Neoplasms · United States, Australia, Belgium and more3Active, not recruitingKaryopharm TherapeuticsMay 22, 2026257
NCT05354362Lymphoma, Large B-Cell, Diffuse · China1TerminatedAntengeneFeb 6, 20237
NCT05265975Lymphoma, Large B-Cell, Diffuse · China2TerminatedAntengeneDec 31, 202454
NCT04854434Colorectal Neoplasms · United States2TerminatedKaryopharm TherapeuticsJun 24, 202213
NCT04782687Multiple Myeloma · United States2Active, not recruitingSarah Cannon Research InstituteMay 31, 202673
NCT04768881Melanoma · United States2TerminatedKaryopharm TherapeuticsSep 22, 202315
NCT04562389Primary Myelofibrosis · United States, Australia, Belgium and more3Active, not recruitingKaryopharm TherapeuticsFeb 20, 2026353
NCT04562870Primary Myelofibrosis · United States, China, France and more2Active, not recruitingKaryopharm TherapeuticsSep 2026112
NCT04519476Multiple Myeloma · United States1RecruitingOncotherapeuticsDec 29, 202322
NCT04442022Lymphoma, Large B-Cell, Diffuse · United States, China, Israel and more3Active, not recruitingKaryopharm TherapeuticsDec 2026501
NCT04414475Multiple Myeloma · Greece, Israel2RecruitingKaryopharm TherapeuticsJan 2028127
NCT04421378Glioblastoma · United States, Canada2TerminatedKaryopharm TherapeuticsJul 3, 202374
NCT04355676Coronavirus Infections2WithdrawnKaryopharm TherapeuticsAug 30, 20200
NCT04349098Coronavirus Infections · United States, Austria, France and more2CompletedKaryopharm TherapeuticsOct 5, 2020190
NCT04256707Carcinoma, Non-Small-Cell Lung · Israel2CompletedKaryopharm TherapeuticsJul 31, 202480
NCT03992339Lymphoma, Large B-Cell, Diffuse · China2CompletedAntengeneMay 31, 202360
NCT03944057Recurrence · China2CompletedAntengeneFeb 25, 202282
NCT03555422Endometrial Neoplasms · United States, Belgium, Canada and more3CompletedKaryopharm TherapeuticsJan 22, 2022263
NCT03110562Multiple Myeloma · United States, Australia, Austria and more3CompletedKaryopharm TherapeuticsFeb 18, 2020402
NCT02628704Multiple Myeloma · United States2WithdrawnKaryopharm TherapeuticsJun 20170
NCT02606461Liposarcoma · United States, Belgium, Canada and more3CompletedKaryopharm TherapeuticsOct 28, 2020342
NCT02431351Myelodysplastic Syndromes2WithdrawnKaryopharm TherapeuticsDec 20170
NCT02389543Multiple Myeloma2WithdrawnKaryopharm TherapeuticsJan 20180
NCT02367690Diabetic Foot · New Zealand2WithdrawnKaryopharm TherapeuticsMay 20150
NCT02336815Multiple Myeloma · United States, Austria, Belgium and more2CompletedKaryopharm TherapeuticsJul 26, 2019202
NCT02314247Lymphoma, T-Cell, Peripheral · Australia, Singapore2TerminatedKaryopharm TherapeuticsJan 201616
NCT02227251Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more2Active, not recruitingKaryopharm TherapeuticsDec 2026244
NCT02213133Carcinoma, Squamous Cell · United States, Canada2TerminatedKaryopharm TherapeuticsDec 10, 201545
NCT02146833Prostatic Neoplasms · United States2TerminatedKaryopharm TherapeuticsApr 1, 201620
NCT02138786Richter's Transformation · United States, Germany, Poland and more2TerminatedKaryopharm TherapeuticsAug 31, 201627
NCT02088541Leukemia, Myeloid, Acute · United States, Canada, Denmark and more2CompletedKaryopharm TherapeuticsJan 8, 2018317
NCT02025985Ovarian Neoplasms · Belgium, Denmark2CompletedKaryopharm TherapeuticsJan 24, 2017116
NCT01986348Glioblastoma · United States, Denmark, Netherlands2TerminatedKaryopharm TherapeuticsJan 23, 202076
NCT01896505Sarcoma · United States, Canada1CompletedKaryopharm TherapeuticsOct 21, 201654
NCT01607905Carcinoma, Squamous Cell · United States, Canada, Denmark1CompletedKaryopharm TherapeuticsMar 15, 2016192
NCT01607892Hematologic Neoplasms · United States, Canada, Denmark1CompletedKaryopharm TherapeuticsOct 13, 2015286

How it is read

Names in the registry

  • “Selinexor”, 32 entries
  • “Selinexor (combination therapy)”, 3 entries
  • “Selinexor 40 mg”, 2 entries
  • “Selinexor 60 mg”, 2 entries
  • “ATG-010”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.